News
Datroway is first TROP2 drug for frontline breast cancer
AZ and Daiichi's Datroway has been cleared by the FDA as first-line treatment for triple-negative breast cancer patients ineligible for immunotherapy.
News
Late-breakers to look out for at ASCO 2026
ASCO is just around the corner, and there is the usual fertile crop of high-profile trials to look out for among the late-breaker presentations.
News
NICE changes stance on Genmab's cervical cancer drug
After saying it couldn't recommend Genmab's cervical cancer therapy Tivdak for use by the NHS, reimbursement authority NICE has had a change of heart.
News
Tuneable peptide biotech Parabilis files IPO
Fresh from agreeing a wide-ranging alliance with Regeneron worth up to $2.3bn, Parabilis has joined the IPO queue.
News
MSD's Sac-TMT delivers in first phase 3 readout
MSD's TROP2-targeting antibody-drug conjugate sac-TMT, licensed from China's Kelun, has improved survival in a late-stage endometrial cancer trial.
News
Views & Analysis
Deep Dive
Editor's Picks
Editor's Picks
